The Australian Myasthenia Gravis Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
It is an autoimmune condition which causes problems with the transmission of signals from the nerves to the muscles. Myasthenia Gravis affects the muscles that control eye movement, facial expression, chewing, and swallowing in its early stages. As the condition worsens, neck and limb muscles may be damaged, making it difficult to keep one’s head up, walk upstairs, or raise one’s arms. Breathing may be affected if not treated. It is estimated that myasthenia gravis affects more than 700,000 people worldwide. The incidence rate of Myasthenia Gravis varies with age, gender, and ethnic groups. The incidence is expected to be 1.9 per 100,000 in Australia.
Increased government backing for innovation, as well as increased funding for R&D projects for various cystic fibrosis treatments, will propel the market forward. Rising acceptance of immunotherapies, approval of promising medications, the emergence of biologics, and increased awareness of rare diseases are all driving market expansion.